Skip to content
Epirus Sees Opportunities for Biosimilars Outside U.S. episode artwork

Aug 21, 2014 17 min

Epirus Sees Opportunities for Biosimilars Outside U.S.

from The Bio Report Hosted by Levine Media Group

The regulatory pathway for biosimilars is still a work in progress at the U.S. Food and Drug Administration, but around the world the industry is growing as regulators have resolved issues that remain obstacles in the United States. We spoke to Amit Munshi, CEO of Epirus Biopharmaceuticals, about the opportunities in emerging and developed markets, his company’s strategic approach, and when we’ll see a vibrant biosimilars industry in the United States.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Epirus Sees Opportunities for Biosimilars Outside U.S.

0:00 17:33

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The Bio Report?

This episode is 17 minutes long.

When was this The Bio Report episode published?

This episode was published on August 21, 2014.

Can I download this The Bio Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.